CombiMatrix, a CLIA-certified laboratory, is bringing microarray analysis to the underserved problem of recurrent pregnancy loss as well as to prenatal testing. CombiMatrix performs microarray ...

PathogenDx has announced the release of the first quantitative microarray-based test for cannabis, PDx-Quant™, which can determine whether or not a sample exceeds a state or a federal regulatory ...

Microarray testing, which uses the same invasive methods as karyotyping — by sampling the chorionic villus cells from the placenta, or amniocentesis, which extracts cells and fetal DNA from ...

PathogenDx has announced the release of the first quantitative microarray-based test for cannabis, PDx-Quant™, which can determine whether or not a sample exceeds a state or a federal regulatory ...

Unclear Results After Microarray Testing Many studies have demonstrated the increased detection rate of chromosome abnormalities after microarray testing. With each of these, the clinically ...

PathogenDx's breakthrough technology shifts the pathogen detection paradigm from microbial to molecular testing through its microarray assays, namely DetectX, EnviroX, and QuantX SANTA CLARA ...

AliveDx, the global in-vitro diagnostics company dedicated to advancing patient care, today announced that its MosaiQ® instrument is registered with the U.S. Food and Drug Administration (FDA) as a ...

The global microarray analysis market is projected to experience substantial growth over the forecast period 2023-2033. Moreover, the market value for 2023 was $5,357.9 million and is expected to ...

Next-generation sequencing version of MammaPrint and BluePrint enables decentralized testing in CE-mark jurisdictions like Germany Analysis for Belgian Health Care Package shows MammaPrint yields cost ...